GLUTEN CONTENT IN PHARMACEUTICALS MARKETED IN THE GAZA STRIP
Ramadan, M., Shbair, M., Al-Astal, R. (2023). GLUTEN CONTENT IN PHARMACEUTICALS MARKETED IN THE GAZA STRIP. EKB Journal Management System, 46(1), 339-346. doi: 10.21608/bfsa.2023.301122
Mai Ramadan; Mohammed Shbair; Raghda Al-Astal. "GLUTEN CONTENT IN PHARMACEUTICALS MARKETED IN THE GAZA STRIP". EKB Journal Management System, 46, 1, 2023, 339-346. doi: 10.21608/bfsa.2023.301122
Ramadan, M., Shbair, M., Al-Astal, R. (2023). 'GLUTEN CONTENT IN PHARMACEUTICALS MARKETED IN THE GAZA STRIP', EKB Journal Management System, 46(1), pp. 339-346. doi: 10.21608/bfsa.2023.301122
Ramadan, M., Shbair, M., Al-Astal, R. GLUTEN CONTENT IN PHARMACEUTICALS MARKETED IN THE GAZA STRIP. EKB Journal Management System, 2023; 46(1): 339-346. doi: 10.21608/bfsa.2023.301122

GLUTEN CONTENT IN PHARMACEUTICALS MARKETED IN THE GAZA STRIP

Bulletin of Pharmaceutical Sciences Assiut University
Volume 46, Issue 1, June 2023, Page 339-346  XML PDF (758.07 K)
Document Type: Original Article
DOI: 10.21608/bfsa.2023.301122
View on SCiNiTO View on SCiNiTO
Authors
Mai Ramadan email orcid 1; Mohammed Shbairorcid 2; Raghda Al-Astalorcid 2
1Department of Pharmaceutical Chemistry and Pharmacognosy, Faculty of Pharmacy, Al-Azhar University- Gaza, Gaza, B. O Box: 1277, Palestine
2Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Al-Azhar University- Gaza, Gaza, B. O Box: 1277, Palestine
Abstract
Gluten is a wheat protein which could trigger an immune-mediated inflammatory response causing Celiac disease. Pharmaceuticals are possible source of gluten due to excipients like wheat starch.
This study examined some pharmaceuticals (non-prescription and prescription type) on gluten and partially hydrolyzed gluten fragments content using sandwich and competitive ELISA techniques, respectively.
Partially hydrolyzed gluten fragments were detected in ca. 37% of tested samples (Total: 38). Only 5 samples had gluten concentration above 20 ppm. None of the pharmaceuticals had detectable levels of glutens upon sandwich ELISA application. Oral administration of four dosage forms at recommended doses provided celiacs with a daily gluten intake exceeding the daily tolerance limit. Excipients in patient information leaflet were absent in most cases.
The findings confirmed that pharmaceuticals could increase the burdens of celiac patients. Accordingly, regular examination of pharmaceuticals on gluten content is advised. Further studies are recommended that would include a larger sample size, and analytical methods to determine gluten in pharmaceuticals should be developed. Registration agencies in the Gaza Strip should apply updated regulations of excipients.
Keywords
Gluten; Celiacs; ELISA; Pharmaceuticals
Statistics
Article View: 132
PDF Download: 186